PHARMACOTHERAPY AND LUNG FUNCTION DECLINE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE : A SYSTEMATIC REVIEW

Authors

  • Galih Radityo Prabowo Faculty of Medicine, University of Muhammadiyah Malang, Indonesia Author

DOI:

https://doi.org/10.53555/nnmhs.v9i3.1620

Keywords:

Chronic Obstructive Pulmonary Disease, FEV1, Lung Function, Pharmacotherapy

Abstract

Chronic obstructive pulmonary disease (COPD) is a long-term condition that affects millions of individuals all over the world and is a major contributor to the rise in hospital admission rates. According to projections made by the World Health Organization (WHO), COPD would become the third greatest cause of mortality worldwide by the year 2020. These patients are also very substantial consumers of the resources made available by the health and social care systems. Because there is now no treatment that can reverse the effects of COPD, patients are responsible for their own healthcare and the management of their condition. There is a correlation between the amount of cigarettes smoked and the degree to which COPD is present. The pathophysiology of COPD is intimately tied to the impact that cigarette smoke has on the lungs. Pharmacological trials that were carried out more than three decades ago with the use of short-acting bronchodilators or inhaled glucocorticoids did not succeed in demonstrating a statistically significant slower rate of FEV1 decline in comparison to the placebo group in their intention-to-treat populations. In light of these equivocal data, the belief that smoking cessation is the only treatment that can delay the course of COPD became widespread. Unfortunately, this pessimism has had a negative impact on how the general public views COPD and has decreased interest in alternative therapeutic techniques. Tiotropium had a greater FEV1 than the placebo, and it also reduced the annual reduction in FEV1 after bronchodilator usage in individuals with COPD who were in the GOLD stage 1 or 2 range. FEV1 drop might be stopped by FF or VI. The patients expressed satisfaction with the treatment, which resulted in fewer exacerbations. It seems like fluticasone furoate or vilanterol could slow down the drop in FEV1 levels.

References

Lumb AB. Nunn’s Applied Respiratory Physiology. 8th ed. Philadelphia: Elsevier; 2017.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD. 2017.

Broaddus VC; Mason RJ; Ernst JD; et al. Murray & Nadel’s Textbook of Respiratory Medicine. Philadelphia: Elsevier Saunders; 2016.

Price SA LM. Patofisiologi Konsep Klinis Proses-Proses Penyakit. Jakarta: EGC; 2016.

World Health Organization’s. Chronic obstructive pulmonary disease (COPD). Geneva; 2017.

Kementerian Kesehatan Republik Indonesia. Riset Kesehatan Dasar [Internet] Jakarta; 2018. Available from: http://www.depkes.go.id/resources/download/infoterkini/materi_rakorpop_2018/Hasil Riskesdas 2018.pdf

Adeloye D; Chua S; Lee C; et al. Global and Regional Estimates of COPD Prevalance: Systematic Review and Metaanalysis. J Glob Health. 2015;5(2):17–23.

Currie GP. ABC of COPD. London: Blackwell Publishing; 2011.

Fishman JA, Grippi MA, Kotloff RM, et al. Fishman’s Pulmonary Disease and Disorders Fifth Edition. New York: Elsevier Saunder; 2016.

Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994 Nov;272(19):1497–505.

Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000 May;320(7245):1297–303.

Kohansal R, Martinez-Camblor P, Agustí A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med. 2009 Jul;180(1):3–10.

Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011 Sep;365(13):1184–92.

Zhou Y, Zhong N-S, Li X, Chen S, Zheng J, Zhao D, et al. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease. N Engl J Med. 2017 Sep;377(10):923–35.

Calverley PMA, Anderson JA, Brook RD, Crim C, Gallot N, Kilbride S, et al. Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. Am J Respir Crit Care Med. 2018 Jan;197(1):47–55.

Vestbo J, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet (London, England). 2016 Apr;387(10030):1817–26.

Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD. Respir Med. 2017 Feb;123:8–17.

Thomsen LH, Dirksen A, Shaker SB, Skovgaard LT, Dahlbäck M, Pedersen JH. Analysis of FEV1 decline in relatively healthy heavy smokers: implications of expressing changes in FEV1 in relative terms. COPD J Chronic Obstr Pulm Dis. 2014;11(1):96–104.

Badan Pengawas Obat dan Makanan Republik Indonesia. Antimuskarinik. pionas.pom.go.id.

Zhou Y, Zou Y, Li X, Chen S, Zhao Z, He F, et al. Lung function and incidence of chronic obstructive pulmonary disease after improved cooking fuels and kitchen ventilation: a 9-year prospective cohort study. PLoS Med. 2014;11(3):e1001621.

Guan W-J, Zheng X-Y, Chung KF, Zhong N-S. Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action. Lancet. 2016;388(10054):1939–51.

Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;95–9.

Bhatt SP, Soler X, Wang X, Murray S, Anzueto AR, Beaty TH, et al. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194(2):178– 84.

Downloads

Published

2023-03-24

How to Cite

Prabowo, G. R. (2023). PHARMACOTHERAPY AND LUNG FUNCTION DECLINE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE : A SYSTEMATIC REVIEW. Journal of Advanced Research in Medical and Health Science (ISSN 2208-2425), 9(3), 96-100. https://doi.org/10.53555/nnmhs.v9i3.1620

Similar Articles

1-10 of 241

You may also start an advanced similarity search for this article.